Biological pathways involved in the development of inflammatory bowel disease

被引:3
|
作者
Zemljic, Mateja [1 ]
Pejkovic, Bozena [1 ]
Krajnc, Ivan [2 ]
Lipovsek, Saska [3 ]
机构
[1] Univ Maribor, Fac Med, Inst Anat Histol & Embryol, SLO-2000 Maribor, Slovenia
[2] Univ Maribor, Fac Med, Dept Internal Med, SLO-2000 Maribor, Slovenia
[3] Univ Maribor, Fac Med, Dept Cell Biol, SLO-2000 Maribor, Slovenia
关键词
Apoptosis; Autophagy; Necrosis; Inflammatory bowel disease; Homeostasis; TUMOR-NECROSIS-FACTOR; INTESTINAL EPITHELIAL-CELLS; INNATE IMMUNE-RESPONSE; CROHNS-DISEASE; ADAPTIVE IMMUNITY; ESCHERICHIA-COLI; AUTOPHAGY GENES; CANCER-THERAPY; FACTOR-ALPHA; MYCOBACTERIUM-TUBERCULOSIS;
D O I
10.1007/s00508-014-0592-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Apoptosis, autophagy and necrosis are three distinct functional types of the mammalian cell death network. All of them are characterized by a number of cell's morphological changes. The inappropriate induction of cell death is involved in the pathogenesis of a number of diseases. Pathogenesis of inflammatory bowel diseases (ulcerative colitis, Crohn's disease) includes an abnormal immunological response to disturbed intestinal microflora. One of the most important reason in pathogenesis of chronic inflammatory disease and subsequent multiple organ pathology is a barrier function of the gut, regulating cellular viability. Recent findings have begun to explain the mechanisms by which intestinal epithelial cells are able to survive in such an environment and how loss of normal regulatory processes may lead to inflammatory bowel disease (IBD). This review focuses on the regulation of biological pathways in development and homeostasis in IBD. Better understanding of the physiological functions of biological pathways and their influence on inflammation, immunity, and barrier function will simplify our expertice of homeostasis in the gastrointestinal tract and in upgrading diagnosis and treatment.
引用
收藏
页码:626 / 633
页数:8
相关论文
共 50 条
  • [21] Extraintestinal Manifestations and Complications in Inflammatory Bowel Disease: From Shared Genetics to Shared Biological Pathways
    van Sommeren, Suzanne
    Janse, Marcel
    Karjalainen, Juha
    Fehrmann, Rudolf
    Franke, Lude
    Fu, Jingyuan
    Weersma, Rinse K.
    INFLAMMATORY BOWEL DISEASES, 2014, 20 (06) : 987 - 994
  • [22] Biological therapy for chronic inflammatory bowel disease
    Dueker, G.
    Lentze, M. J.
    MONATSSCHRIFT KINDERHEILKUNDE, 2007, 155 (02) : 118 - 126
  • [23] Targets for inflammatory bowel disease - biological therapy
    MacDonald, TT
    IBD AND SALICYLATES - 5, 2001, 24 (01): : 61 - 65
  • [24] Biological dietary treatment of inflammatory bowel disease
    Thomas, Tallberg
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2009, 44 : 51 - 51
  • [25] Immunogenicity of biological agents in inflammatory bowel disease
    Fefferman, DS
    Farrell, RJ
    INFLAMMATORY BOWEL DISEASES, 2005, 11 (05) : 497 - 503
  • [26] The role of biological therapy in inflammatory bowel disease
    Su, CYG
    Judge, TA
    Lichtenstein, GR
    DRUGS OF TODAY, 2001, 37 (02) : 121 - 133
  • [27] HLA-DRB1 is involved in the development of antibodies to infliximab in Inflammatory Bowel Disease
    Billiet, T.
    Vande Casteele, N.
    Van Stappen, T.
    Cleynen, I.
    Ballet, V.
    Claes, K.
    Princen, F.
    Singh, S.
    Gils, A.
    Ferrante, M.
    Van Assche, G.
    Vermeire, S.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S429 - S429
  • [28] Biological Therapy for Inflammatory Bowel Disease in Children
    Na, So Young
    Shim, Jung Ok
    PEDIATRIC GASTROENTEROLOGY HEPATOLOGY & NUTRITION, 2012, 15 (01) : 13 - 18
  • [29] New biological therapies in inflammatory bowel disease
    van Deventer, SJH
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2003, 17 (01) : 119 - 130
  • [30] Novel biological therapies for inflammatory bowel disease
    Stokkers P.C.F.
    Hommes D.W.
    Current Treatment Options in Gastroenterology, 2006, 9 (3) : 201 - 210